Outcomes for Patients with Hypertension, Diabetes and Heart Disease in the Coronavirus Pandemic: Impact of Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers Treatment

Grant number: unknown

Grant search

Key facts

  • Disease

    COVID-19
  • Funder

    American Heart Association
  • Principal Investigator

    Unspecified Paul Heidenreich
  • Research Location

    United States of America
  • Lead Research Institution

    Stanford University
  • Research Priority Alignment

    N/A
  • Research Category

    Clinical characterisation and management

  • Research Subcategory

    Prognostic factors for disease severity

  • Special Interest Tags

    N/A

  • Study Type

    Clinical

  • Clinical Trial Details

    Unspecified

  • Broad Policy Alignment

    Pending

  • Age Group

    Unspecified

  • Vulnerable Population

    Unspecified

  • Occupations of Interest

    Unspecified

Abstract

Working with the VA Palo Alto Health Care System, Stanford Health Care and Northern California Kaiser, this team will study the use of ACE and ARBs on patients with high blood pressure or diabetes during the COVID-19 pandemic to determine trends in the rates of COVID-19 infection, influenza, medication adherence, hospitalizations and deaths to improve patient management practices.